The Discovery: Zhu et al. 2015
Quercetin is a plant flavonoid found widely in onions, apples, capers, and many other fruits and vegetables — but its role in longevity science goes back to a specific, hypothesis-driven discovery rather than a broad dietary-antioxidant claim.
Zhu, Tchkonia, Pirtskhalava, et al. published "The Achilles' heel of senescent cells: from transcriptome to senolytic drugs" in Aging Cell (2015). The researchers analyzed gene expression in senescent cells and found upregulated pro-survival networks — including ephrins (EFNB1/3), PI3Kδ, p21, BCL-XL, and plasminogen-activated inhibitor-2 — that senescent cells rely on to resist apoptosis. Using siRNA to silence these survival nodes selectively killed senescent cells without harming proliferating or quiescent healthy cells.
From there, the team screened existing drugs for compounds that could pharmacologically hit these same targets. Dasatinib (an FDA-approved leukemia drug) proved effective at eliminating senescent human fat-cell progenitors, while quercetin was more effective against senescent human endothelial cells and mouse bone-marrow-derived mesenchymal stem cells (BM-MSCs). Combined, dasatinib plus quercetin (D+Q) eliminated senescent mouse embryonic fibroblasts more completely than either compound alone — the first validated senolytic drug combination.
In Vivo Effects
In mouse models — chronologically aged, radiation-exposed, and progeroid (Ercc1-/Δ) mice — D+Q reduced senescent cell burden. In old mice, cardiac function and carotid vascular reactivity improved within 5 days of a single dose. In mice that had one limb irradiated, a single D+Q dose led to improved exercise capacity that persisted for at least 7 months after treatment — a striking duration for a single intervention, and part of why senolytics as a drug class generated so much research interest.
The Human Pilot: Hickson et al. 2019
Hickson, Prata, Bobart, et al. published "Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease" in EBioMedicine (2019;47:446-456) — the first published human evidence for a senolytic intervention.
The open-label pilot trial in people with diabetic kidney disease measured senescence markers before and after a short D+Q dosing course. The trial reported decreased adipose tissue macrophages and crown-like structures, reduced skin epidermal p16INK4A+ and p21CIP1+ senescent cells, and reduced circulating SASP factors including IL-1α, IL-6, and matrix metalloproteinases MMP-9 and MMP-12.
Beyond Senolytics: Mast-Cell Stabilization and Antioxidant Activity
Quercetin's research history predates the senolytic field by decades. It has long been studied as a mast-cell stabilizer — inhibiting histamine and pro-inflammatory cytokine release from mast cells and basophils — which is why it appears in many seasonal-allergy and histamine-intolerance supplement formulations, independent of any senolytic claim. It's also a broadly studied dietary antioxidant and inhibitor of NF-κB and the NLRP3 inflammasome, two of the major drivers of chronic low-grade inflammation.
These are mechanistically distinct use cases from the D+Q senolytic protocol, and someone taking quercetin for allergy/histamine support is using a different dose and rationale than someone taking it as part of a senolytic pulse protocol.
Quercetin vs. Fisetin
| Property | Quercetin | Fisetin |
|---|---|---|
| Discovery context | First identified senolytic (2015, paired with dasatinib) | Most potent single-flavonoid senolytic in a 10-compound Mayo screen (2018) |
| Primary mechanism | PI3K/Akt inhibition, targets endothelial/BM-MSC senescent cells | BCL-2/BCL-XL inhibition, broader tissue activity |
| Human trial evidence | Open-label pilot (Hickson 2019, corrigendum 2020) | Ongoing trials (e.g. AFFIRM-LITE) |
| Non-senolytic uses | Mast-cell stabilizer, antihistamine-adjacent, NLRP3 inhibitor | Less established outside senolytic/neuroprotective use |
| Bioavailability | Poor (<10% standard); phytosome forms improve absorption | Poor (<10% standard); phytosome forms improve absorption |
| Typically used with | Dasatinib (prescription) or fisetin (OTC combination) | Quercetin, piperine |
Dosing Protocols
In the D+Q senolytic research, quercetin doses generally ranged from 500-1000 mg alongside dasatinib on a pulsed 2-day schedule. In OTC longevity stacks that pair quercetin with fisetin instead of prescription dasatinib, quercetin is typically dosed at 500-1000 mg during the same pulse window as fisetin.
The StackProtocol Senolytic Stack
Quercetin + Fisetin Senolytic Pulse Protocol
The OTC-accessible version of the senolytic concept — pairing two complementary flavonoids with a bioavailability enhancer
Evidence Summary
| Study / Source | Finding | Evidence Level |
|---|---|---|
| Zhu et al. 2015 Aging Cell |
Identified dasatinib + quercetin as the first senolytic drug combination; D+Q eliminated senescent cells in aged, irradiated, and progeroid mice; improved cardiac/vascular function within 5 days; single dose extended exercise capacity for 7+ months in irradiated mice | Preclinical (foundational discovery) |
| Hickson et al. 2019 (corrigendum 2020) EBioMedicine 47:446-456 |
Open-label pilot in diabetic kidney disease patients; reduced senescent cell markers and circulating SASP factors after D+Q dosing; conclusions revised after 2020 raw-data re-analysis | Human pilot trial (preliminary, revised) |